PRIVACY POLICY

Effective Date: August 21, 2020

Millicent Pharma Limited (“Millicent Pharma” “we,” “our,” or “us”), provides this privacy policy (“Privacy Policy”) to describe how we collect, use, and share the information of individuals who visit our websites at femring.com, us.intrarosa.com, or any other website we own or operate or that links to this Privacy Policy (the “Site(s)”). Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as terms defined in our Terms of Service.

Information Collection

When using our Sites or interacting with us, you may voluntarily provide information about yourself, including your name, email address, and any other information you choose to provide. We collect this information when you send an email to us requesting information or interact with us for any other purpose.

We collect information relating to your interactions with us and our Site, including browser type, IP address, pages visited and other activities on the Site, device type, and time and date of visit, and other information we collect through the use of cookies and similar technology.

Information Use

We may use your information for any lawful purpose, including the following:

  • To respond to your inquiries;
  • To operate and improve our services, including to provide better services, products, and opportunities to our customers and visitors to our Sites;
  • To operate, personalize, and improve our Sites, including for analytics purposes;
  • To send surveys, promotions, and marketing materials that may be of interest to you;
  • To comply with the law and to maintain the security of our Sites; or
  • With your consent, or as otherwise disclosed at the time information is collected.

Information Sharing

We may share the information we collect with third parties, including the following:

  • With service providers who perform various functions on our behalf;
  • As part of a corporate sale, merger, or acquisition, or other transfer of all or part of our assets, including as part of a bankruptcy proceeding;
  • Pursuant to a subpoena, court order, governmental inquiry, or other legal process or as otherwise required by law, or to protect our rights or the rights of third parties;
  • With your consent or as otherwise disclosed at the time of data collection or sharing.

We may share information that has been de-identified or aggregated without limitation.

Analytics

We may work with third parties that collect data about your use of our Sites and other sites or apps over time for non-advertising purposes. Millicent Pharma uses Google Analytics and other third-party services to improve the performance of our Sites and for analytics and marketing purposes. For more information about how Google Analytics collects and uses data when you use our Site, visit www.google.com/policies/privacy/partners, and to opt out of Google Analytics, visit tools.google.com/dlpage/gaoptout.

Third-Party Links and Tools

Our Sites may provide links to third-party websites or apps. We do not control the privacy practices of those websites or apps, and they are not covered by this Privacy Policy. You should review the privacy policies of other websites or apps that you use to learn about their data practices.

Our Sites may also include integrated social media tools or “plug-ins,” such as social networking tools offered by third parties. If you use these tools to share personal information or you otherwise interact with these features on the Site, those companies may collect information about you and may use and share such information in accordance with your account settings, including by sharing such information with the general public. Your interactions with third-party companies and your use of their features are governed by the privacy policies of the companies that provide those features. We encourage you to carefully read the privacy policies of any accounts you create and use.

Your California Privacy Rights

Under the California Consumer Protection Act (“CCPA”), California residents have certain rights with respect to the personal information collected by businesses. This section contains disclosures required by the CCPA and applies only to “personal information” about California consumers that is subject to the CCPA (“California Personal Information”).

California Personal Information We Collect and Share for a Business Purpose. We collect the following categories of California Personal Information:

Categories of California Personal Information Collected Disclosed for business purposes to the following categories of third parties:
Personal and online identifiers (such as first and last name, email address, or unique online identifiers) All categories listed below.
Categories of information described in Section 1798.80(e) of the California Civil Code (such as physical characteristics or description, insurance policy number, bank account number, credit card number, debit card number, or any other financial information, medical information, or health insurance information) All categories listed below.
Characteristics of protected classifications under California or federal law (such as race or gender) All categories listed below.
Commercial or transactions information (such as records of personal property or products or services purchased, obtained or considered) All categories listed below.
Internet or other electronic network activity information (such as browsing history, search history, interactions with a website, email, application, or advertisement) All categories listed below.
Biometric information (such as call recordings) All categories listed below.
Geolocation information All categories listed below.

 

Categories of Sources. We and our service providers, acting on our behalf, collect California Personal Information from the following categories of sources:

  • From consumers;
  • From service providers we have engaged to provide services to us or on our behalf;
  • From our affiliates; and
  • From non-affiliated third parties, such as pharmacies or copay programs that may collect personal information on our behalf.

Why We Use and Disclose California Personal Information. We and our service providers, acting on our behalf, use and disclose California Personal Information we collect for our commercial and business purposes, as further described in this Privacy Policy. These purposes include, without limitation:

  • Our commercial purposes, including marketing and facilitating transactions.
  • Our business purposes as identified in the CCPA, which include:
    • Auditing related to our interactions with you;
    • Detecting and protecting against security incidents, fraud, and illegal activity;
    • Debugging;
    • Performing services (for us or our service provider) such as account servicing, processing orders and payments, and analytics;
    • Internal research for technological improvement;
    • Activities to maintain and improve our services; and
    • Other one-time uses.

Recipients of California Personal Information. We disclose the categories of California Personal Information designated above for business purposes to the categories of third parties listed below:

  • Service providers;
  • Affiliates not under the Millicent brand; and
  • Data analytics providers.

Your Rights Regarding California Personal Information. California residents have certain rights with respect to the personal information collected by businesses. If you are a California resident, you may exercise the following rights regarding your California Personal Information, subject to certain exceptions and limitations:

  • The right to access the categories and specific pieces of personal information we have collected about you;
  • The right to request the categories of sources from which we collected your personal information, our purposes for collecting your personal information, the categories of your personal information that we have disclosed for a business purpose, and the categories of third parties with which we have shared personal information; and
  • The right to request that we delete the personal information we have collected from you.

To exercise any of the above rights, please contact us:

Note that we may need to request additional information from you to verify your identity or understand the scope of your request, although you will not be required to create an account with us to submit a request or have it fulfilled.

Nevada Privacy Rights

Under Nevada law, Nevada residents may submit a request directing us not to make certain disclosures of personal information we maintain about them.

To exercise this right, please contact us:

Changes to Our Privacy Policy

If our information practices change, we will post these changes on this page. We encourage you to visit this page periodically to learn of any updates.

Contact Us

If you have questions, comments, or concerns about this Privacy Policy, please contact us at:
privacy@millicentpharma.com.

IMPORTANT SAFETY INFORMATION AND INDICATION

The most important information you should know about Femring® (estradiol acetate vaginal ring) (an estrogen hormone)
  • Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using Femring. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
  • Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline in brain function).
  • Using estrogen-alone may increase your chances of getting strokes or blood clots.
  • Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older.
  • Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia.
  • Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.
  • Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.
  • You and your healthcare provider should talk regularly about whether you still need treatment with Femring.

Femring is a prescription vaginal ring that contains estradiol (an estrogen hormone). Femring should be removed after 90 days of continuous use. If you and your healthcare provider decide you should continue using Femring, a new ring can be inserted in your vagina.

Femring is used after menopause to reduce moderate to severe hot flushes and treat moderate to severe menopausal changes in and around the vagina.

Do not start using Femring if you have unusual vaginal bleeding; currently have or have had certain cancers, blood clots, or liver problems; had a stroke or heart attack; have been diagnosed with a bleeding disorder; are allergic to Femring or any of its ingredients; or think you might be pregnant.

Before you use Femring, tell your healthcare provider if you have any unusual vaginal bleeding, have any problems with your vagina or cervix (lower end of your womb), have any other medical conditions, are going to have surgery or will be on bed rest, or are breastfeeding. Also tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements.

Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed.

Serious, but less common side effects include heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, liver problems, changes in your thyroid hormone levels, and enlargement of benign tumors of the uterus (“fibroids”).

Less serious, but common side effects include headache; breast tenderness or pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps; bloating, nausea and vomiting; hair loss; fluid retention; vaginal yeast infection; and reactions from inserting Femring such as burning, irritation, and itching.

Call your healthcare provider right away if you have any of the following warning signs, or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pains in your chest or legs with or without shortness of breath, weakness and fatigue.

For more information, talk with your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to Millicent Pharma at 1-877-810-2101 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information, including BOXED WARNING, Patient Information, and Instructions for Use.

Femring is a registered trademark and the Millicent Pharma logo is a trademark of Millicent Pharma Limited.

IMPORTANT SAFETY INFORMATION AND INDICATION

The most important information you should know about Femring® (estradiol acetate vaginal ring) (an estrogen hormone)
  • Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using Femring. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
  • Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline in brain function).
  • Using estrogen-alone may increase your chances of getting strokes or blood clots.
  • Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older.
  • Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia.
  • Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.
  • Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.
  • You and your healthcare provider should talk regularly about whether you still need treatment with Femring.

Femring is a prescription vaginal ring that contains estradiol (an estrogen hormone). Femring should be removed after 90 days of continuous use. If you and your healthcare provider decide you should continue using Femring, a new ring can be inserted in your vagina.

Femring is used after menopause to reduce moderate to severe hot flushes and treat moderate to severe menopausal changes in and around the vagina.

Do not start using Femring if you have unusual vaginal bleeding; currently have or have had certain cancers, blood clots, or liver problems; had a stroke or heart attack; have been diagnosed with a bleeding disorder; are allergic to Femring or any of its ingredients; or think you might be pregnant.

Before you use Femring, tell your healthcare provider if you have any unusual vaginal bleeding, have any problems with your vagina or cervix (lower end of your womb), have any other medical conditions, are going to have surgery or will be on bed rest, or are breastfeeding. Also tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements.

Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed.

Serious, but less common side effects include heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, liver problems, changes in your thyroid hormone levels, and enlargement of benign tumors of the uterus (“fibroids”).

Less serious, but common side effects include headache; breast tenderness or pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps; bloating, nausea and vomiting; hair loss; fluid retention; vaginal yeast infection; and reactions from inserting Femring such as burning, irritation, and itching.

Call your healthcare provider right away if you have any of the following warning signs, or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pains in your chest or legs with or without shortness of breath, weakness and fatigue.

For more information, talk with your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to Millicent Pharma at 1-877-810-2101 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information, including BOXED WARNING, Patient Information, and Instructions for Use.
Femring is a registered trademark and the Millicent Pharma logo is a trademark of Millicent Pharma Limited.
IMPORTANT SAFETY INFORMATION AND INDICATION
The most important information you should know about Femring® (estradiol acetate vaginal ring) (an estrogen hormone)
  • Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using Femring. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
  • Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline in brain function).
  • Using estrogen-alone may increase your chances of getting strokes or blood clots.
  • Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older.
  • Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia.
  • Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.
  • Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.
  • You and your healthcare provider should talk regularly about whether you still need treatment with Femring.

Femring is a prescription vaginal ring that contains estradiol (an estrogen hormone). Femring should be removed after 90 days of continuous use. If you and your healthcare provider decide you should continue using Femring, a new ring can be inserted in your vagina.

Femring is used after menopause to reduce moderate to severe hot flushes and treat moderate to severe menopausal changes in and around the vagina.

Do not start using Femring if you have unusual vaginal bleeding; currently have or have had certain cancers, blood clots, or liver problems; had a stroke or heart attack; have been diagnosed with a bleeding disorder; are allergic to Femring or any of its ingredients; or think you might be pregnant.

Before you use Femring, tell your healthcare provider if you have any unusual vaginal bleeding, have any problems with your vagina or cervix (lower end of your womb), have any other medical conditions, are going to have surgery or will be on bed rest, or are breastfeeding. Also tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements.

Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed.

Serious, but less common side effects include heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, liver problems, changes in your thyroid hormone levels, and enlargement of benign tumors of the uterus (“fibroids”).

Less serious, but common side effects include headache; breast tenderness or pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps; bloating, nausea and vomiting; hair loss; fluid retention; vaginal yeast infection; and reactions from inserting Femring such as burning, irritation, and itching.

Call your healthcare provider right away if you have any of the following warning signs, or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pains in your chest or legs with or without shortness of breath, weakness and fatigue.

For more information, talk with your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to Millicent Pharma at 1-877-810-2101 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information, including BOXED WARNING, Patient Information, and Instructions for Use.
Femring is a registered trademark and the Millicent Pharma logo is a trademark of Millicent Pharma Limited.

© 2021, Millicent Pharma Limited. All rights reserved.
Quayside Business Park, Dundalk, A91 KA9R, Ireland

01/2019
FEM012

© 2021, Millicent Pharma Limited. All rights reserved.
Quayside Business Park, Dundalk, A91 KA9R, Ireland

01/2019
FEM012